SBIOALPS Medical Breakthroughs ETF
Seeks investment results that correspond to the performance of the S-Network Medical Breakthroughs Index.
By ALPS · Launched 2014
Annual Cost
0.50%
#2,766 of 6,040 · average
Fund Size
$240M
#2,301 of 6,040 · mid-size
Return (1Y)
+78.4%
Track Record
11 years
#1,253 of 6,040 · established
Performance
Total-return NAV · USDGrowth of $10,000
$16,181+61.8%
Total-return NAV, USD. Net of fund fees, before tax.
What's inside
How Beacon categorizes this fundAsset class
EquityRegion
GlobalCap
Smid
Strategy
Index tracking
Sector
Health careFocus
Biotech & Genomics
Index tracked
S-Network Medical Breakthroughs Index
Holdings
By weightConcentration
Top 10 holdings = 30.5% of funddiversified
Kymera Therapeutics Inc
4.7%
Celcuity Inc
3.3%
Alkermes Plc
3.2%
Cg Oncology Inc
3.1%
Mirum Pharmaceuticals Inc
3.1%
Amicus Therapeutics Inc
2.9%
Acadia Pharmaceuticals Inc
2.7%
Newamsterdam Pharma Co Nv
2.6%
Crinetics Pharmaceuticals Inc
2.5%
Apogee Therapeutics Inc
2.5%
Asset allocation
Stocks
100.0%
By sector
Healthcare
100.0%
Risk profile
Last 12 months · Sharpe & Sortino need 3+ yearsVolatility (1Y)
31.2%High
Year-on-year price swings
Max drawdown
-63.1%Severe
Worst peak-to-trough loss
Sharpe (3Y)
0.88Decent risk-adjusted returns
Sortino (3Y)
1.30Good downside protection
Listing
- Exchange
- NYSE Arca
Full fund details
- Objective
- Seeks investment results that correspond to the performance of the S-Network Medical Breakthroughs Index.
- Strategy
- Employs a passive management approach designed to track small and mid-cap biotechnology stocks listed on U.S. exchanges, with market capitalizations between $200 million and $5 billion. Invests at least 80% of net assets in securities that comprise the Underlying Index.
- Inception date
- December 30, 2014
- Fund family
- ALPS
Similar funds
Same asset class, closest by strategy & exposureNext steps
Save SBIO to compare it with other funds, or start building a portfolio.
Data updated on 2026-09-18